The multiagency "Tox21" research initiative aims to improve regulatory hazard assessment of substances potentially harmful to humans and the environment. This research initiative uses in vitro high throughput screening (HTS) assays to evaluate the biological activity of compounds in a 10,000 compound library and to map the observed activities to toxicity pathways. One of the goals of the Tox21 effort is to incorporate in vitro assay data into models that can be used to predict toxic (or adverse) effects in humans resulting from chemical exposures.
To achieve its aims, the Tox21 initiative needs assays that assess the effects of chemicals on targets encompassing all pathways relevant to toxicity. The Assays and Pathways Working Group of the Tox21 Consortium is accepting nominations for in vitro HTS toxicity assays, particularly assays that identify toxicity pathway markers for either initiating or downstream events. Assays that evaluate the following pathways are of greatest interest:
Nominated assays will be assessed for their overall applicability to the Tox21 HTS program in terms of biological relevance, cost, and potential to be adapted to an HTS platform. Suitable assays will then be optimized to the HTS platform and validated for use in the program.
Nominations should consider the following general criteria:
Assay nominations should be submitted to Kristine Witt, NTP Chair, Assays and Pathways Working Group. When submitting HTS assay nominations and protocol information, please provide the following contact information for the submitter:
NTP prefers electronically submitted nominations, but will accept nominations by the means that is most convenient for the submitter.
The Tox21 Consortium is a multiagency collaboration among
The Tox21 partner agencies work together to develop, validate, and translate innovative in vitro HTS methods to characterize the impact of chemicals on key steps in toxicity pathways.
Data collected in the Tox21 initiative will be used in the near term to prioritize uncharacterized compounds for regulatory testing using both traditional and novel test methods. The eventual goal of Tox21 is to use HTS methods to generate data that will allow risk assessors to more accurately predict the effects of uncharacterized substances on human health and the environment.
More information about partner agencies' activities in support of Tox21 can be found on the agency websites:
NICEATM’s mission, in part, is to facilitate the development, validation, and regulatory acceptance of new and revised test methods while maintaining and promoting scientific quality. The strategies used to accomplish NICEATM’s mission can be leveraged to support the Tox21 initiative while promoting the reduction, refinement, and replacement of animal use for regulatory toxicity testing.